- Holmes DR, Reddy VY, Turi ZG, et al; PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009;374(9689):534–542. doi:10.1016/S0140-6736(09)61343-X.
- Holmes DR, Jr, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64(1):1–12. doi:10.1016/j.jacc.2014.04.029.
- Freeman JV, Varosy P, Price MJ, et al. The NCDR left atrial appendage occlusion registry. J Am Coll Cardiol. 2020;75(13):1503–1518. doi:10.1016/j.jacc.2019.12.040.
- Sepahpour A, Ng M, Storey P, et al. Death from pulmonary artery erosion complicating implantation of percutaneous left atrial appendage occlusion device. Heart Rhythm. 2013;10(12):1810–1811. doi:10.1016/j.hrthm.2013.07.046.
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 35, 2022 - Issue 6
Case Studies
Large hemopericardium and pericardial tamponade from presumed erosion of a Watchman 2.5 device 1-year postimplantation
Raveen Chawlaa Division of Cardiology, Department of Medicine, Baylor Scott & White Medical Center – Temple, Temple, TexasCorrespondence[email protected]
https://orcid.org/0000-0001-8213-0017
, MDhttps://orcid.org/0000-0001-8213-0017, , MD & , MD